2022
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds A, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George T, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kaesberg P, Kuykendall A, Madanat Y, McMahon B, Mohan S, Nadiminti K, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein B, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward D, Bergman M, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 1033-1062. PMID: 36075392, DOI: 10.6004/jnccn.2022.0046.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesMyeloproliferative neoplasmsClinical practice guidelinesEssential thrombocythemiaPolycythemia veraRisk stratificationManagement of myeloproliferative neoplasmsOverproduction of blood cellsPhiladelphia chromosome-negative myeloproliferative neoplasmsDiagnosis of myeloproliferative neoplasmsPractice guidelinesClonal blood disorderManagement of myelofibrosisCourse of treatmentSupportive care strategiesAssessment of symptomsNCCN GuidelinesDiagnostic workupCare strategiesMultidisciplinary panelBlood disordersHeterogeneous groupSymptom statusBlood cellsNCCN
2014
Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia
Zhang B, Lee AI, Podoltsev N. Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia. Oxford Medical Case Reports 2014, 2014: 138-140. PMID: 25988058, PMCID: PMC4369993, DOI: 10.1093/omcr/omu053.Peer-Reviewed Original ResearchTumor lysis syndromeAcute hemolytic episodesLysis syndromeHemolytic episodesHigh riskPeripheral blood smear findingsG6PD deficiencyTime of presentationBlood smear findingsChronic lymphocytic leukemiaG6PD-deficient patientsAfrican American menRed blood cellsTransfusion supportSerious complicationsClinical parametersSmear findingsAcute anemiaHematologic emergencyLymphocytic leukemiaTumor cellsBlood streamPatientsBlood cellsOxidative stress
2009
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian patients (pts) with 5-FU and capecitabine (CAP)-related toxicity
Podoltsev N, Saif M. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian patients (pts) with 5-FU and capecitabine (CAP)-related toxicity. Journal Of Clinical Oncology 2009, 27: e14588-e14588. DOI: 10.1200/jco.2009.27.15_suppl.e14588.Peer-Reviewed Original ResearchDeleterious mutationsCommon deleterious mutationSequence variationSequence analysisFull sequence analysisGenetic variantsMutationsFull sequencingDihydropyrimidine dehydrogenase gene polymorphismsDPYD mutationsGenetics laboratoriesSimple identificationDPYDDPYD geneGenesD949VSequencingDNAEnzymeToxicityIVS14CatabolismSequencePolymorphismBlood cells